Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy

por Masatoshi Kudo
Publicado 2021

A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion

por Masatoshi Kudo
Publicado 2021

Artificial intelligence-based endoscopic diagnosis of colorectal polyps using residual networks.

por Yoriaki Komeda, Hisashi Handa, Ryoma Matsui, Shohei Hatori, Riku Yamamoto, Toshiharu Sakurai, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Tomohiro Watanabe, Masatoshi Kudo
Publicado 2021

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease

por Satoru Hagiwara, Naoshi Nishida, Kazuomi Ueshima, Yasunori Minami, Yoriaki Komeda, Tomoko Aoki, Masahiro Takita, Masahiro Morita, Hirokazu Chishina, Akihiro Yoshida, Hiroshi Ida, Masatoshi Kudo
Publicado 2021

Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma.

por Naoshi Nishida, Masatoshi Kudo, Takafumi Nishimura, Tadaaki Arizumi, Masahiro Takita, Satoshi Kitai, Norihisa Yada, Satoru Hagiwara, Tatsuo Inoue, Yasunori Minami, Kazuomi Ueshima, Toshiharu Sakurai, Naosuke Yokomichi, Takeshi Nagasaka, Ajay Goel
Publicado 2013

Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

por Satoru Hagiwara, Tomohiro Watanabe, Masatoshi Kudo, Kosuke Minaga, Yoriaki Komeda, Ken Kamata, Masatomo Kimura, Hidetoshi Hayashi, Kazuhiko Nakagawa, Kazuomi Ueshima, Yasunori Minami, Tomoko Aoki, Masahiro Takita, Masahiro Morita, Hirokazu Cishina, Hiroshi Ida, Ah-Mee Park, Naoshi Nishida
Publicado 2021

Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma

por Petros Fessas, Muntaha Naeem, Matthias Pinter, Thomas U. Marron, David Szafron, Lorenz Balcar, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Elad Sharon, Alessio Cortellini, David J. Pinato
Publicado 2021

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

por Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021